- Home
- WINT vs XXII Comparison
WINT vs XXII Comparison
Compare WINT & XXII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WINT
- XXII
- Stock Information
- Founded
- WINT 1992
- XXII 1998
- Country
- WINT United States
- XXII United States
- Employees
- WINT N/A
- XXII N/A
- Industry
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- XXII Medicinal Chemicals and Botanical Products
- Sector
- WINT Health Care
- XXII Health Care
- Exchange
- WINT Nasdaq
- XXII Nasdaq
- Market Cap
- WINT 2.2M
- XXII 2.0M
- IPO Year
- WINT 1995
- XXII N/A
- Fundamental
- Price
- WINT $0.92
- XXII $3.33
- Analyst Decision
- WINT Hold
- XXII
- Analyst Count
- WINT 1
- XXII 0
- Target Price
- WINT $350.00
- XXII N/A
- AVG Volume (30 Days)
- WINT 25.7M
- XXII 2.6M
- Earning Date
- WINT 08-18-2025
- XXII 08-12-2025
- Dividend Yield
- WINT N/A
- XXII N/A
- EPS Growth
- WINT N/A
- XXII N/A
- EPS
- WINT N/A
- XXII N/A
- Revenue
- WINT N/A
- XXII $23,869,000.00
- Revenue This Year
- WINT N/A
- XXII $22.41
- Revenue Next Year
- WINT N/A
- XXII $76.35
- P/E Ratio
- WINT N/A
- XXII N/A
- Revenue Growth
- WINT N/A
- XXII N/A
- 52 Week Low
- WINT $0.36
- XXII $2.86
- 52 Week High
- WINT $737.44
- XXII $2,390.85
- Technical
- Relative Strength Index (RSI)
- WINT 54.04
- XXII 23.05
- Support Level
- WINT $0.91
- XXII $2.86
- Resistance Level
- WINT $1.20
- XXII $3.40
- Average True Range (ATR)
- WINT 0.22
- XXII 0.84
- MACD
- WINT 0.01
- XXII 0.26
- Stochastic Oscillator
- WINT 23.61
- XXII 7.11
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.
About XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.